Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) – Research analysts at SVB Leerink issued their Q4 2024 earnings per share estimates for Fate Therapeutics in a research report issued on Thursday, May 4th. SVB Leerink analyst D. Graybosch anticipates that the biopharmaceutical company will post earnings of ($0.45) per share for the quarter. SVB Leerink […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. Fate Therapeutics had a negative return on equity of 50.86% and a negative net margin of 292.55%. The firm had […]
Fate Therapeutics (NASDAQ:FATE – Get Rating) released its earnings results on Wednesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.36, Briefing.com reports. The firm had revenue of $58.98 million during the quarter, compared to the consensus estimate of $33.53 million. Fate Therapeutics had a […]
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) traded down 9.3% on Tuesday . The company traded as low as $5.72 and last traded at $5.77. 679,137 shares traded hands during trading, a decline of 80% from the average session volume of 3,473,137 shares. The stock had previously closed at $6.36. Analyst Ratings Changes […]
Should You Buy or Sell Fate Therapeutics Stock? Get The Latest FATE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.